Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab.
Journal: Drugs
Published: October 10, 2024
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.
Journal: Journal for immunotherapy of cancer
Published: March 23, 2023
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
Journal: Cancer discovery
Published: August 21, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 28, 2020
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 03, 2019
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 05, 2018
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Journal: Journal for immunotherapy of cancer
Published: September 18, 2018
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 20, 2018
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Journal: The Lancet. Oncology
Published: April 02, 2018
Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 15, 2018
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Journal: The Lancet. Oncology
Published: January 23, 2018
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 29, 2017
Last Updated: 09/26/2026